Q1 2027 Senores Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- Senores Pharmaceuticals Ltd (NSE:SENORES) reported a robust 36% year-over-year revenue growth in Q1 FY27, driven by strong performance in regulated markets.
- The company has nearly doubled its ANDA approved portfolio from 30 to 58 in the past year, with 23 already commercialized.
- Emerging markets revenue grew by 30% in Q1 FY27, with the business now being cash flow positive.
- The company expects revenue growth of approximately 30% to 40% and PAT growth of about 50% to 60% for FY27.
- Senores Pharmaceuticals Ltd (NSE:SENORES) has a strong and diversified pipeline of 39 molecules under development, providing visibility for future growth.
- The EBITDA margin for the emerging market business decreased from 20% in Q4 FY26 to 14% in Q1 FY27.
- The branded generics segment experienced a 2% decline in revenue, with a strategic shift towards profitability over sales growth.
- There was a sequential decline in gross margins, attributed to higher growth in regulated markets versus emerging markets.
- The company has scaled down its sterile injectable project, reallocating IPO proceeds to expand oral solid capacities.
- Concerns were raised about potential tariffs on generic medications imported to the US, which could impact future operations.
Ladies and Gentlemen, good day and welcome to Senores Pharmaceuticals Q1 and FY27 Earning Conference Call hosted by DAM Capital Advisors.
(Operator Instructions) Please note that this conference is being recorded. This conference call may contain forward-looking statement.
About the company which are based on the beliefs, opinions and expectation of the company as on date of this call. These statements are not the guarantee of future performance and involve risk and uncertainties that are difficult to predict.
I now hand the conference over to Ms. Payal Shah from DAM Capital. Thank you and over to you Payal.
Good evening, everyone, and a warm welcome on behalf of Gant Capital Advisors to the Q1 FY '27 earnings call of Senores Pharmaceuticals.
On the call today, we have Mr. Swapnil Shah, Promoter and Managing Director Mr. Sanjay Majmudar, Chairman and Mr. Deval Shah, Whole-time Director and Chief Financial Officer of Senores Pharmaceuticals.
We will begin the call with opening
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
